Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,955 total articles
CVS has quietly become a healthcare-services hybrid: strong cash generation, targeted AI and venture investments, and a diversified revenue mix justify a tactical long. At $104.73 the stock offers asymmetric upside to consensus targets while valuation metrics (EV/EBITDA 13.4, P/S 0.33) keep risk manageable. Trade plan below balances upside to $115 …
Chipotle has been punished for slowing sales and margin compression. The setup today is a mean-reversion trade: valuations imply recovery if same-store sales stabilize and restaurant-level margins recover. I like a mid-term long (45 trading days) that targets $42 while keeping risk defined at $31.
United Therapeutics offers a rare combination in biotech: durable product revenue, strong free cash flow, and fresh clinical catalysts. Against speculative names that trade on preclinical promises, UTHR's balance sheet, buybacks and Phase III wins make it the practical choice for a trade that prioritizes profits over possibility. This plan lays out…
Ascendis has moved from pure R&D to a commercial-stage endocrinology franchise. Positive five-year TransCon PTH data, a new pediatric approval, a Nasdaq ordinary-share listing and share buybacks have set the stage for revenue growth. Technical momentum is strong, and the balance of fundamental catalysts versus execution risk supports an initiating …
Mastercard’s dominant payments network and recurring, high-margin cash flows make it a compelling long trade today. At $539.35 the stock looks expensive on headline multiples, but structural advantages, steady free cash flow ($17.8B) and new product rollouts (Click to Pay, tokenization, stablecoin consortium work) give the company room to grow into…
BE Semiconductor (BESIY) has pulled back from its 52-week high but still sits as a direct beneficiary of rising AI-focused semiconductor packaging and assembly spending. The stock offers an asymmetric mid-term trade: high reward if AI capex holds, but elevated valuation and cyclical downside risk demand a tight stop. Trade plan: enter $295, target …
PVH sold off after a regional slowdown hit guidance. The business still generates strong free cash flow, trades at low multiples, and carries modest leverage. If geopolitical pressures in EMEA ease, PVH offers asymmetric upside from current levels with defined risk controls.
Kyverna's registrational SPS data validated miv-cel's mechanism and cleared the first commercial hurdle. The market still prices the company like a single-indication biotech. With a market cap near $540M, low net leverage, and a deep autoimmune pipeline (gMG, lupus nephritis), KYTX offers a compelling asymmetric risk/reward for an event-driven long…
Victory Capital (VCTR) combines inorganic scale from the Amundi US deal, durable fee-bearing assets across mutual funds, ETFs and institutional channels, plus shareholder returns that support the thesis. At $87.80, the shares trade at ~18.7x earnings with free cash flow of $422M and a market cap near $5.48B. I recommend a tactical long for mid-term…
EquipmentShare is trading near its 52-week low while executing a refinancing and board refresh. The company's T3 initiative (newer connected rental product) increases the optionality of recurring rental revenue. We lay out a mid-term trade: enter $19.00, stop $17.50, target $26.00, horizon 45 trading days.
Nano Labs (NA) is a $40M micro-cap fabless semiconductor firm pivoting into AI hardware and data-center infrastructure. The stock sits near $1.73 with a PE of 1.8 and PB of 0.37, heavy short interest, and a string of product and partnership announcements. I recommend a speculative long as a mid-term trade: entry $1.70, stop $1.20, target $3.50, hor…
Hillman Solutions (HLMN) is trading at an attractive entry after a pullback toward its 52-week low. The business mixes recurring, low-tech distribution with growing robotics/digital offerings and recent acquisitions that add roughly $30M in expected net sales for fiscal 2026. At roughly $1.6B market cap and an EV/EBITDA under 10, a disciplined long…
Micron reported a blowout fiscal quarter with $41.5B revenue, gargantuan margins and multi-year customer agreements that lock in a large share of DRAM and NAND volumes. The stock has run hard; I recommend buying a disciplined pullback to $900 with a $1,500 target and $800 stop — horizon ~180 trading days — because the fundamentals and cash flow pro…
NXP Semiconductors trades at $276.80 but carries fundamentals and forward catalysts that argue for a tactical long into earnings. With a $69B market cap, 2026 free cash flow of ~$2.71B, a reasonable P/E of 26 and accelerating data-center and automotive revenue, the risk/reward favors buying the dip ahead of results. This trade lays out an entry, st…
Centene's business is being re-priced not because healthcare demand vanished but because administrative frictions and subsidy rollbacks have turned membership math volatile. Membership losses, a weak 2026 outlook and stretched valuations after a sharp rally create a tactical short opportunity. The company still generates meaningful free cash flow, …
GlobalFoundries (GFS) is a capital-heavy foundry that is increasingly exposed to AI infrastructure spend and specialty RF/advanced packaging demand. Recent technical weakness creates a tactical entry for a swing trade into a recovering demand backdrop, near-term earnings catalysts and a 3D packaging ramp. Entry $72.00, target $90.00, stop $64.00; m…
Solid Power (SLDP) is a speculative buy here because the company’s sizable cash/liquidity position shields downside while commercialization milestones in Korea and an expanding pilot line create asymmetric upside. Entry at $2.50, stop $2.10, target $5.00 for a mid-term (45 trading days) swing that bets on positive execution and sentiment re-rating.
Nu Holdings is trading at a valuation that looks reasonable relative to its profitability and growth runway. Recent quarters show accelerating revenue and strong unit economics, management authorized a $1B buyback, and operating returns are healthy. This trade idea lays out a pragmatic long with entry, stop and targets over a 180-trading-day horizo…
lululemon has been punished for softer near-term sales and a China PR hit, but the shares now trade at single-digit multiples with healthy margins and cash flow. We upgrade to a constructive stance and outline a swing trade with defined entry, stop and target tied to a repositioning thesis and measurable catalysts.
TransDigm offers a strong aftermarket business, oversized operating margins, and recurring free cash flow that can compound tax-efficiently in a taxable account. Valuation is rich but tolerable for investors seeking capital gains and occasional large distributions; treat new positions as long-term holds with a clear stop in case of margin or balanc…
Ciena's share-price weakness in June created a tactical long opportunity. With market cap near $59.8B, a strong free-cash-flow base and industry reports pointing to multi-year optics demand from hyperscalers, the stock looks set to recover as orders convert. This trade targets $550 over a 180-trading-day horizon with a $360 stop; position size shou…
Nu Holdings is trading like a struggling bank while still delivering high growth, sizeable free cash flow, and management actions that reduce supply. I recommend a long trade sized as a tactical position: entry $13.50, stop $11.00, target $18.00 over a 180-trading-day horizon. The risk/reward favors buyers if execution in Mexico/Colombia and margin…
Black Diamond Therapeutics reported encouraging Phase 2 results for silevertinib (BDTX-1535) in frontline EGFR non-classical NSCLC, showing a 60% ORR, median PFS of 15.2 months and 86% CNS response. With a market cap of about $115M, recent commentary implies roughly $118M in cash — an uncommon setup where the equity is trading at or below net cash …
Cal-Maine (CALM) is trading like a cyclical commodity name but exhibits balance-sheet strength and recurring free cash flow that argue for a value-oriented long. With a market cap near $3.97B, free cash flow of $720M and no debt, the stock screens cheap on P/E (~5.7) and EV/EBITDA (~3.8). This trade targets a recovery in egg prices and margin norma…
Amkor (AMKR) is a direct beneficiary of AI-driven packaging demand. A 10-year TSMC agreement, a Q1 beat and upbeat Q2 guide give a compelling catalyst mix. The drop to $69.59 offers a measured entry for a mid-term swing while maintaining defined downside protection.
